Targeting CYP4A attenuates hepatic steatosis in a novel multicellular organotypic liver model

Area of Science:

• Hepatology and Regenerative Medicine
• 3D Cell Culture and Organoid Technology
• In Vitro Disease Modeling

Background:

• Non-alcoholic fatty liver disease (NAFLD) progresses from simple steatosis to severe liver damage and failure.
• Limited therapeutic options exist due to a lack of reliable human in vitro models for studying NAFLD progression and developing treatments.

Purpose of the Study:

• To develop a novel 3D human cell-based hepatic model for simulating non-alcoholic fatty liver disease (NAFLD) steatosis.
• To validate the model's utility for target identification and drug evaluation in NAFLD.

Main Methods:

• Generation of 3D hepatic spheroids using HepaRG cells, vascular endothelial cells, and mesenchymal stem cells in a soft matrix.
• Development of a 3D hepatic steatosis model using excess glucose and palmitate.
• Inhibition of cytochrome P450 4A (CYP4A) using HET0016 or siRNA to assess therapeutic effects.

Main Results:

• The 3D hepatic model demonstrated efficient self-organization and functional competence, accurately recapitulating steatosis phenotypes.
• Key steatosis markers, including neutral lipid accumulation and altered lipogenesis/gluconeogenesis gene expression, were observed.
• Inhibition of CYP4A ameliorated steatosis, reduced endoplasmic reticulum stress, and improved insulin signaling, validating CYP4A as a therapeutic target.

Conclusions:

• A novel, easily generated 3D human hepatic model reliably simulates NAFLD steatosis pathology.
• The model is validated for target validation and drug evaluation, with CYP4A identified as a promising therapeutic target.
• This translational platform holds significant potential for advancing NAFLD drug development.